AVS Bio and ExpediteBio have partnered to close the gap between discovery and manufacturing requirements.
Public source
Publisher name
Public post
You may have seen the news over the summer: AVS Bio and ExpediteBio have partnered. Here is why it matters for your programme. Great antibodies rarely fail on mode of ac…
Company
AVS Bio
Driving innovation, AVS Bio delivers SPF eggs, antibodies, proteins, and custom biologics for global health.
- Industry
- Pharmaceutical Manufacturing
- Location
- Norwich, US
- Company size
- 51–200 employees
About AVS Bio
AVS Bio | Biologics Start Here For more than 60 years, AVS Bio has been a trusted partner in scientific innovation, providing core biological materials and services that fuel breakthroughs in human, animal, and environmental health. We deliver more than reagents, we deliver discovery. From SPF eggs and avian reagents to antibodies, proteins, and custom biologics services, our solutions support researchers, developers, and manufacturers worldwide. What we offer: • Avian Products & Biologicals: SPF eggs, avian reagents, and antigens for research and diagnostics • Antibodies & Proteins: engineered and optimized for immunology, diagnostics, and therapeutics • Custom Biologics Services: immunization, antibody discovery, protein engineering, and development support Why AVS Bio? • Experience you can trust: 60+ years of expertise, USDA-licensed products, and reliable large-scale production • Flexible & scalable: support tailored to your needs, from small projects to full development partnerships • Scientific rigor: more than a supplier, we are a partner advancing innovation with deep technical expertise At AVS Bio, we believe the future of health innovation starts with the right biological tools and true collaboration. Let’s work together to accelerate discovery and bring new solutions to life.
See moreLatest activity
Latest activity from AVS Bio
8 signals
Presence & Recognition
AVS Bio is hosting a working session called What Makes the Cut on antibody programs with a small team, a fixed budget, and a board date that will not move at the Cambridge Innovation Center in Kendall Square on Monday, September 28, 2026.
Presence & Recognition
AVS Bio hosted a working session on building an antibody program called What Makes the Cut? on Monday 28 September at the Cambridge Innovation Center.
Presence & Recognition
AVS Bio is exhibiting at the Carterra booth at Discovery on Target 2026, showcasing case studies addressing kinetic profiling and workflow scalability.
Discover more
Similar signals
Similar public activity from other companies.
Partnerships
WuXi XDC
WuXi XDC developed the novel WuXiDARx conjugation platform, which is valuable at the discovery stage to streamline ADC engineering and identify optimal DAR when screening antibody/linker-payload combos, and at the CMC stage to accelerate CMC development, reduce development risks, and eventual large-scale manufacturing costs by simplified CMC process.
Partnerships
Lifecore Biomedical
Lifecore Biomedical signed an agreement for commercial site transfer supporting a global pharmaceutical company.
Partnerships
Unolab Manufacturing
Unolab Manufacturing has expanded its role beyond traditional contract manufacturing to support pharmaceutical companies in reducing complexity and accelerating their path to market.
Partnerships
ChromaGenix
ChromaGenix is partnering with Sunresin to expand access to AAV purification technologies across Asia.
Partnerships
Enzene Biosciences Ltd